Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

计划入组 1,500 人 · 首次发布于 2026 年 2 月 2 日

An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

计划入组 100 人 · 首次发布于 2025 年 4 月 11 日

A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia

计划入组 250 人 · 首次发布于 2026 年 9 月 3 日

Xanomeline Tartrate and Trospium Chloride

Xanomeline

C₁₄H₂₃N₃OS

Trospium Chloride/Xanomeline

CAIRNS AND HINTERLAND HOSPITAL AND HEALTH SERVICE

Australia

Endocrinology and Metabolism

China

Dupont Nutrition And Health

United States

Xanomeline-Trospium Shows Consistent Efficacy in Schizophrenia Across Pooled Phase 3 Trials

Bristol Myers Squibb Presents New COBENFY Data for Schizophrenia Treatment at Psych Congress

Cobenfy Shows Sustained Efficacy and Safety in Long-Term Schizophrenia Trials